Dr. Abida on using PARP inhibitors in mCRPC patients with non-BRCA1/2 HRR gene alterations
Wassim Abida, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses whether he would recommend FDA-approved PARP inhibitors (ie, olaparib, rucaparib) in patients with metastatic castration-resistant prostate cancer (mCRPC) harboring alterations in homologous recombination repair (HRR) genes other than BRCA1/2. In the pivotal PROFOUND trial of olaparib in mCRPC, researchers examined PARP inhibition in patients with at least 1 of 15 different genes with a direct or indirect role in HRR: BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L. In the video, Abida explains how the specific mutation type determines whether or not he feels comfortable recommending a PARP inhibitor for a patient.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
